Anorexia NervosaOASISNCT07353151
Artificial Intelligence-based, Virtual Reality Application to Provide Data- Driven, Patient-centred Treatment for People With Eating Disorders
A study testing OASIS virtual reality (VR) program in people with Anorexia Nervosa and Feeding and Eating Disorders, run by King's College London.
Trial summary
The goal of this clinical trial is to see if a short virtual reality (VR) program can be used safely and comfortably with people receiving care for anorexia nervosa. The study will also check if people are willing to take part and complete the full week of VR sessions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Anorexia Nervosa, Feeding and Eating Disorders
- What is being tested?
- OASIS virtual reality (VR) program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- No sites listed yet
- Study dates
- Jan 2026to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults ≥18 years.
- Anorexia nervosa receiving or awaiting treatment as usual (TAU) within South London and Maudsley NHS Foundation Trust (inpatient, day service, or outpatient).
- Medically stable and clinically suitable to take part in brief VR sessions alongside TAU (as judged by the treating team).
- Able to give informed consent.
Who cannot join
- Current or recent (within 12 months) serious self-harm with suicidal intent, or behaviour that posed a risk to life (e.g., overdose, deep cutting, swallowing sharp objects), or self-harm likely to cause lasting impairment.
- Active suicidality or high risk of suicide.
- Untreated or unstable epilepsy.
- Psychotic disorder.
- Outpatient participants with BMI < 10.
- Current participation in another research study or clinical trial.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this clinical trial is to see if a short virtual reality (VR) program can be used safely and comfortably with people receiving care for anorexia nervosa. The study will also check if people are willing to take part and complete the full week of VR sessions.
The main questions the study will answer are:
Read more
Can the investigators recruit and keep participants in the study? Do participants complete most of the VR sessions? Do they find the experience helpful and acceptable? Are there any side effects, like nausea or dizziness?
Participants will:
- Take part in one VR session each weekday (about 20 to 30 minutes) for one week
- Continue their usual care during this time
- Answer questions before and after the VR sessions about their anxiety, mood, motivation, and experience
- Some participants may join a short interview or focus group to share feedback
The VR program includes scenes for food-related exposure, calming music, motivational phrases, and goal setting. The app was designed with help from people with lived experience of anorexia and based on psychological therapies used in treatment.
Who can take part:
- Adults aged 18 or older
- People receiving or waiting for care for anorexia nervosa at South London and Maudsley NHS Foundation Trust (SLaM)
- People who are medically stable and able to give informed consent
Why this matters:
This study will help researchers understand if using VR in eating disorder services is practical, safe, and acceptable. The results will help plan a larger trial in the future to see if this type of VR treatment can support recovery from anorexia nervosa. Taking part is voluntary, and participants can stop at any time.
Read the detailed description
This single-site, open-label feasibility clinical trial will test a brief virtual reality (VR) program (OASIS) delivered alongside treatment as usual for adults with anorexia nervosa. OASIS was co-developed by South London and Maudsley NHS Foundation Trust (SLaM), King's College London, and SyncVR Medical UK with input from people with lived experience.
The VR sessions are designed to support recovery by providing:
- Food-related exposure scenes to practise approaching commonly avoided foods
- Relaxing environments with music
- Motivational prompts and goal-setting within the VR experience
Participants complete five supervised VR sessions over one week (about 20-30 minutes each) in inpatient, day service, or outpatient settings. A clinician or trained researcher is present for all sessions. Pacing can be adjusted, and sessions can be paused or stopped at any time.
Feasibility will be assessed using study process measures (for example, recruitment and retention, session completion, and brief usability/acceptability feedback) and session logs. Safety is monitored during every session and via routine clinical information already collected in care; no additional research blood tests are required.
Participants complete brief assessments at baseline and after the one-week intervention. These include validated self-report measures of eating-disorder symptoms, food-related fear, mood/anxiety, and motivation, plus very short ratings around sessions to track immediate experience (for example, anxiety or relaxation). A subset may take part in a short interview or focus group to describe what felt helpful or difficult and suggest refinements.
There is no randomization or control arm in this feasibility phase. Findings will be used to decide whether and how to run a larger randomized controlled trial, including practical procedures (for example, session dose and outcome burden), expected adherence, safety monitoring steps, and willingness to be randomized.
- Conditions
- Anorexia Nervosa, Feeding and Eating Disorders
- Being tested
- OASIS virtual reality (VR) program
- Keywords
- Anorexia nervosa (AN), Virtual reality (VR), Eating disorders, Food exposure, Feasibility study, Food-related anxiety, Exposure-based intervention, South London and Maudsley (SLaM), King's College London (KCL), United Kingdom
- Medical subject headings
- Anorexia Nervosa, Feeding and Eating Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OASIS virtual reality (VR) programBehavioural
Immersive VR sessions including (a) food-related exposure scenes, (b) relaxing music, and (c) motivational prompts and goal-setting. Delivered once daily on weekdays for one week (five sessions; ≈20-30 minutes each), supervised by a clinician or trained researcher. Sessions may be paused or stopped at any time.
| Study group | Role | What they receive |
|---|---|---|
| OASIS VR + Treatment as Usual (TAU) | Experimental | Single-group, open-label feasibility arm. Participants receive a brief virtual reality (VR) program (OASIS) alongside treatment as usual. The VR program is delivered as five supervised sessions over one week (≈20-30 minutes per session) in inpatient, day service, or outpatient settings. Receives: Behavioral: OASIS virtual reality (VR) program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Session adherence to the VR intervention
Proportion of scheduled VR sessions completed per participant, recorded from session logs. A session counts as completed if ≥20 minutes are delivered. Primary endpoint = % of participants who complete ≥4 of 5 sessions; the investigators will also report mean (SD) sessions completed.
Measured: Baseline to end of Week 1 (5 weekdays)
Secondary outcomes (11)
Recruitment and retention feasibility
Recruitment = % of eligible approached who consent. Retention = % of consented who complete the 1-week assessment.
Measured: Months 2-10 (recruitment) and Baseline to end of Week 1 (retention)
EDE-Q Global Score
Change in global score on the Eating Disorder Examination Questionnaire (EDE-Q) from baseline to end of Week 1. Score (0-6); higher scores indicate greater severity of eating disorder symptoms.
Measured: Baseline and end of Week 1
EFQ Total Score
Change in total score on the Eating and Food Questionnaire (EFQ) from baseline to end of Week 1.
Units: Score (0-50); higher scores indicate more maladaptive eating behaviors.
Measured: Baseline and end of Week 1
FOFM Score
Change in score on the Fear of Food Measure (FOFM) from baseline to end of Week 1.
Units: Score (0-40); higher scores indicate greater food-related anxiety.
Measured: Baseline and end of Week 1
M3VAS Items
Change in visual analog scale ratings (M3VAS) for mood and anxiety from baseline to end of Week 1.
Units: Score (0-100 mm); higher scores indicate greater symptom severity.
Measured: Baseline and end of Week 1
DASS-42 Total Score
Change in total score on the Depression Anxiety Stress Scales (DASS-42) from baseline to end of Week 1. Units: Score (0-126); higher scores indicate greater psychological distress.
Measured: Baseline and end of Week 1
Acceptability/usability of VR
Study-specific 0-10 ratings of acceptability/helpfulness (higher = better); summarized as mean (SD).
Measured: End of Week 1
Willingness outcomes
(a) Willingness to try foods encountered in VR outside sessions (four 0-10 items: willingness, readiness, confidence, 1-week likelihood); (b) willingness to participate in a future randomized trial (Yes/No).
Measured: End of Week 1
Feasibility of assessment battery
Completion rates across all planned questionnaires; instruments with >25% missing at either time point flagged as infeasible for a future trial.
Measured: Baseline and end of Week 1
Safety (adverse events and VR-related symptoms)
Counts/types of adverse events (including nausea, dizziness, headache); % of participants with ≥1 event.
Measured: During sessions through end of Week 1
Body Mass Index (BMI)
Change in body mass index (BMI) from baseline to end of Week 1. Units: kg/m²; higher values indicate higher body mass.
Measured: Baseline and end of Week 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2026
- Study startJan 2026 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Anorexia NervosaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single-group, open-label feasibility design. All participants receive the OASIS VR add-on alongside treatment as usual across inpatient, day service, or outpatient settings. The intervention consists of five supervised sessions over one week (≈20-30 minutes each). No randomization or control arm in this phase; focus is on feasibility, acceptability, adherence, and safety.
- Masking
- None (open label)
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hubertus Himmerich, MD, PhD, Principal investigator, South London and Maudsley NHS Foundation Trust; King's College LondonJanet Treasure, MD, PhD, Study chair, South London and Maudsley NHS Foundation Trust; King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07353151
- Sponsor's protocol ID
- IRAS: 359405
- Acronym
- OASIS
- Status last verified
- Jan 2026
- First submitted
- 13 Nov 2025
- Last updated
- 21 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Sharing of de-identified individual participant data (IPD) is under consideration pending sponsor and NHS approvals, information governance review, and repository selection. Aggregate results will be published. An IPD sharing statement will be updated once approvals are in place.
Publications
Cardi V, Krug I, Perpina C, Mataix-Cols D, Roncero M, Treasure J. The use of a nonimmersive virtual reality programme in anorexia nervosa: a single case-report. Eur Eat Disord Rev. 2012 May;20(3):240-5. doi: 10.1002/erv.1155. Epub 2011 Sep 20.
PubMed 21932282Bektas S, Natali L, Rowlands K, Valmaggia L, Di Pietro J, Mutwalli H, Himmerich H, Treasure J, Cardi V. Exploring Correlations of Food-Specific Disgust with Eating Disorder Psychopathology and Food Interaction: A Preliminary Study Using Virtual Reality. Nutrients. 2023 Oct 19;15(20):4443. doi: 10.3390/nu15204443.
PubMed 37892518Natali L, Meregalli V, Rowlands K, Di Pietro J, Treasure J, Collantoni E, Meneguzzo P, Tenconi E, Favaro A, Fontana F, Ceccato E, Sala A, Valmaggia L, Cardi V. Virtual food exposure with positive mood induction or social support to reduce food anxiety in anorexia nervosa: A feasibility study. Int J Eat Disord. 2024 Mar;57(3):703-715. doi: 10.1002/eat.24155. Epub 2024 Feb 17.
PubMed 38366755Young KS, Rennalls SJ, Leppanen J, Mataix-Cols D, Simmons A, Suda M, Campbell IC, O'Daly O, Cardi V. Exposure to food in anorexia nervosa and brain correlates of food-related anxiety: findings from a pilot study. J Affect Disord. 2020 Sep 1;274:1068-1075. doi: 10.1016/j.jad.2020.05.077. Epub 2020 May 25.
PubMed 32663934
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Artificial Intelligence-based, Virtual Reality Application to Provide Data- Driven, Patient-centred Treatment for People With Eating Disorders
- ClinicalTrials.gov ID
- NCT07353151
- Acronym / sponsor ID
- OASIS / IRAS: 359405
- Conditions
- Anorexia Nervosa, Feeding and Eating Disorders
- Keywords
- Anorexia nervosa (AN), Virtual reality (VR), Eating disorders, Food exposure, Feasibility study, Food-related anxiety, Exposure-based intervention, South London and Maudsley (SLaM)
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- King's College LondonUniversity, hospital or other
- Study start
- Jan 2026 (estimated)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 20 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to see if a short virtual reality (VR) program can be used safely and comfortably with people receiving care for anorexia nervosa. The study will also check if people are willing to take part and complete the full week of VR sessions.
The main questions the study will answer are:
Can the investigators recruit and keep participants in the study? Do participants complete most of the VR sessions? Do they find the experience helpful and acceptable? Are there any side effects, like nausea or dizziness?
Participants will:
- Take part in one VR session each weekday (about 20 to 30 minutes) for one week
- Continue their usual care during this time
- Answer questions before and after the VR sessions about their anxiety, mood, motivation, and experience
- Some participants may join a short interview or focus group to share feedback
The VR program includes scenes for food-related exposure, calming music, motivational phrases, and goal setting. The app was designed with help from people with lived experience of anorexia and based on psychological therapies used in treatment.
Who can take part:
- Adults aged 18 or older
- People receiving or waiting for care for anorexia nervosa at South London and Maudsley NHS Foundation Trust (SLaM)
- People who are medically stable and able to give informed consent
Why this matters:
This study will help researchers understand if using VR in eating disorder services is practical, safe, and acceptable. The results will help plan a larger trial in the future to see if this type of VR treatment can support recovery from anorexia nervosa. Taking part is voluntary, and participants can stop at any time.
Detailed description
This single-site, open-label feasibility clinical trial will test a brief virtual reality (VR) program (OASIS) delivered alongside treatment as usual for adults with anorexia nervosa. OASIS was co-developed by South London and Maudsley NHS Foundation Trust (SLaM), King's College London, and SyncVR Medical UK with input from people with lived experience.
The VR sessions are designed to support recovery by providing:
- Food-related exposure scenes to practise approaching commonly avoided foods
- Relaxing environments with music
- Motivational prompts and goal-setting within the VR experience
Participants complete five supervised VR sessions over one week (about 20-30 minutes each) in inpatient, day service, or outpatient settings. A clinician or trained researcher is present for all sessions. Pacing can be adjusted, and sessions can be paused or stopped at any time.
Feasibility will be assessed using study process measures (for example, recruitment and retention, session completion, and brief usability/acceptability feedback) and session logs. Safety is monitored during every session and via routine clinical information already collected in care; no additional research blood tests are required.
Participants complete brief assessments at baseline and after the one-week intervention. These include validated self-report measures of eating-disorder symptoms, food-related fear, mood/anxiety, and motivation, plus very short ratings around sessions to track immediate experience (for example, anxiety or relaxation). A subset may take part in a short interview or focus group to describe what felt helpful or difficult and suggest refinements.
There is no randomization or control arm in this feasibility phase. Findings will be used to decide whether and how to run a larger randomized controlled trial, including practical procedures (for example, session dose and outcome burden), expected adherence, safety monitoring steps, and willingness to be randomized.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single-group, open-label feasibility design. All participants receive the OASIS VR add-on alongside treatment as usual across inpatient, day service, or outpatient settings. The intervention consists of five supervised sessions over one week (≈20-30 minutes each). No randomization or control arm in this phase; focus is on feasibility, acceptability, adherence, and safety.
| Arm | Type | Receives |
|---|---|---|
| OASIS VR + Treatment as Usual (TAU) | Experimental | Behavioral: OASIS virtual reality (VR) programSingle-group, open-label feasibility arm. Participants receive a brief virtual reality (VR) program (OASIS) alongside treatment as usual. The VR program is delivered as five supervised sessions over one week (≈20-30 minutes per session) in inpatient, day service, or outpatient settings. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults ≥18 years.
- Anorexia nervosa receiving or awaiting treatment as usual (TAU) within South London and Maudsley NHS Foundation Trust (inpatient, day service, or outpatient).
- Medically stable and clinically suitable to take part in brief VR sessions alongside TAU (as judged by the treating team).
- Able to give informed consent.
Key exclusion criteria (6 listed)
- Current or recent (within 12 months) serious self-harm with suicidal intent, or behaviour that posed a risk to life (e.g., overdose, deep cutting, swallowing sharp objects), or self-harm likely to cause lasting impairment.
- Active suicidality or high risk of suicide.
- Untreated or unstable epilepsy.
- Psychotic disorder.
- Outpatient participants with BMI < 10.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OASIS virtual reality (VR) programImmersive VR sessions including (a) food-related exposure scenes, (b) relaxing music, and (c) motivational prompts and goal-setting. Delivered once daily on weekdays for one week (five sessions; ≈20-30 minutes each), supervised by a clinician or trained researcher. Sessions may be paused or stopped at any time. | Behavioural | OASIS VR + Treatment as Usual (TAU) |
Primary outcome
Session adherence to the VR intervention
Time frame: Baseline to end of Week 1 (5 weekdays)
Proportion of scheduled VR sessions completed per participant, recorded from session logs. A session counts as completed if ≥20 minutes are delivered. Primary endpoint = % of participants who complete ≥4 of 5 sessions; the investigators will also report mean (SD) sessions completed.
11 secondary outcomes
Recruitment and retention feasibility
Time frame: Months 2-10 (recruitment) and Baseline to end of Week 1 (retention)
EDE-Q Global Score
Time frame: Baseline and end of Week 1
EFQ Total Score
Time frame: Baseline and end of Week 1
FOFM Score
Time frame: Baseline and end of Week 1
M3VAS Items
Time frame: Baseline and end of Week 1
DASS-42 Total Score
Time frame: Baseline and end of Week 1
Acceptability/usability of VR
Time frame: End of Week 1
Willingness outcomes
Time frame: End of Week 1
Feasibility of assessment battery
Time frame: Baseline and end of Week 1
Safety (adverse events and VR-related symptoms)
Time frame: During sessions through end of Week 1
Body Mass Index (BMI)
Time frame: Baseline and end of Week 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Background: PubMed 21932282Cardi V, Krug I, Perpina C, Mataix-Cols D, Roncero M, Treasure J. The use of a nonimmersive virtual reality programme in anorexia nervosa: a single case-report. Eur Eat Disord Rev. 2012 May;20(3):240-5. doi: 10.1002/erv.1155. Epub 2011 Sep 20.
- Background: PubMed 37892518Bektas S, Natali L, Rowlands K, Valmaggia L, Di Pietro J, Mutwalli H, Himmerich H, Treasure J, Cardi V. Exploring Correlations of Food-Specific Disgust with Eating Disorder Psychopathology and Food Interaction: A Preliminary Study Using Virtual Reality. Nutrients. 2023 Oct 19;15(20):4443. doi: 10.3390/nu15204443.
- Background: PubMed 38366755Natali L, Meregalli V, Rowlands K, Di Pietro J, Treasure J, Collantoni E, Meneguzzo P, Tenconi E, Favaro A, Fontana F, Ceccato E, Sala A, Valmaggia L, Cardi V. Virtual food exposure with positive mood induction or social support to reduce food anxiety in anorexia nervosa: A feasibility study. Int J Eat Disord. 2024 Mar;57(3):703-715. doi: 10.1002/eat.24155. Epub 2024 Feb 17.
- Background: PubMed 32663934Young KS, Rennalls SJ, Leppanen J, Mataix-Cols D, Simmons A, Suda M, Campbell IC, O'Daly O, Cardi V. Exposure to food in anorexia nervosa and brain correlates of food-related anxiety: findings from a pilot study. J Affect Disord. 2020 Sep 1;274:1068-1075. doi: 10.1016/j.jad.2020.05.077. Epub 2020 May 25.
- South London \& Maudsley NHS Foundation Trust - Adult Eating Disorders ServiceLink provided by the sponsor.
- King's College London - Eating \& Weight Research (CREW)Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided. Sharing of de-identified individual participant data (IPD) is under consideration pending sponsor and NHS approvals, information governance review, and repository selection. Aggregate results will be published. An IPD sharing statement will be updated once approvals are in place.
Related trials for Anorexia Nervosa
Active, not recruiting
Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa
Anorexia Nervosa
Recruiting
Specialist Supportive Clinical Management (SSCM) for Children and Adolescents With Anorexia Nervosa and Atypical Anorexia Nervosa
Anorexia Nervosa, Atypical Anorexia Nervosa
Not yet recruitingPhase 2
An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
Anorexia Nervosa
Recruiting
Influence of Control Deprivation on the Use of the Analytical Cognitive Style in Anorexic Subjects
Anorexia Nervosa
Active, not recruiting
A Study on the Effects of Combined FMT on Gut Microbiota and Eating Disorder Symptoms in AN
Anorexia Nervosa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hubertus Himmerich, MD, PhD principal investigator
South London and Maudsley NHS Foundation Trust; King's College London
Janet Treasure, MD, PhD study chair
South London and Maudsley NHS Foundation Trust; King's College London
Questions about this trial
What is this clinical trial studying?
A study testing OASIS virtual reality (VR) program in people with Anorexia Nervosa and Feeding and Eating Disorders, run by King's College London.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wafa A Alharbi (+447404450403, wafa.alharbi@kcl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Session adherence to the VR intervention (time frame: Baseline to end of Week 1 (5 weekdays)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07353151, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.